William Blair Analysts Decrease Earnings Estimates for BRNS

Barinthus Biotherapeutics plc (NASDAQ:BRNS) – William Blair cut their FY2025 earnings per share estimates for shares of Barinthus Biotherapeutics in a report issued on Wednesday, May 7th. William Blair analyst A. Hsieh now forecasts that the company will post earnings of ($1.63) per share for the year, down from their previous forecast of ($1.52). The consensus estimate for Barinthus Biotherapeutics’ current full-year earnings is ($1.38) per share. William Blair also issued estimates for Barinthus Biotherapeutics’ FY2026 earnings at ($1.69) EPS.

Barinthus Biotherapeutics (NASDAQ:BRNS) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.15).

A number of other equities research analysts have also issued reports on BRNS. Alliance Global Partners reaffirmed a “buy” rating on shares of Barinthus Biotherapeutics in a research note on Monday, March 24th. HC Wainwright reiterated a “buy” rating and issued a $3.00 price target on shares of Barinthus Biotherapeutics in a report on Friday, March 21st.

Barinthus Biotherapeutics Price Performance

Shares of NASDAQ:BRNS opened at $0.93 on Monday. The business’s 50 day simple moving average is $0.89 and its 200-day simple moving average is $1.01. The firm has a market capitalization of $37.52 million, a price-to-earnings ratio of -0.62 and a beta of -0.80. Barinthus Biotherapeutics has a 12 month low of $0.64 and a 12 month high of $2.44.

Institutional Trading of Barinthus Biotherapeutics

An institutional investor recently bought a new position in Barinthus Biotherapeutics stock. Gilead Sciences Inc. purchased a new position in shares of Barinthus Biotherapeutics plc (NASDAQ:BRNS) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 620,351 shares of the company’s stock, valued at approximately $749,000. Barinthus Biotherapeutics accounts for approximately 0.0% of Gilead Sciences Inc.’s investment portfolio, making the stock its 14th largest position. Gilead Sciences Inc. owned 1.54% of Barinthus Biotherapeutics as of its most recent filing with the Securities and Exchange Commission. 25.20% of the stock is currently owned by institutional investors and hedge funds.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.